Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tesaglitazar · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Tesaglitazar | DRUG | - |
| Pioglitazone | DRUG | - |
| Dietary and Lifestyle Modification Counseling | BEHAVIORAL | - |
Inclusion Criteria: * Provision of a written informed consent * Men or women who are 30 to 80 years of age * Female patients: postmenopausal or surgically sterile * Diagnosed with type 2 diabetes with C-peptide levels \> 0.8 ng/mL * Treated with diet alone or treatment with a single oral antidiabet...
Top 20 of 31 competitors
Tesaglitazar is an investigational small molecule being studied for the treatment of Type 2 Diabetes. It is a metabolic therapeutic agent developed by AstraZeneca PLC. As of the available data, it is in Phase 2 clinical development and has not been approved for any use.
Tesaglitazar is a small molecule developed for Type 2 Diabetes. The specific molecular target or target class has not been disclosed in the available information. Therefore, its mechanism of action is not detailed here.
Tesaglitazar is being developed by AstraZeneca PLC, a pharmaceutical company listed on the stock exchange under the ticker AZN. The drug is currently in Phase 2 clinical trials for Type 2 Diabetes.
Tesaglitazar is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and there are no active trials currently listed for this asset.
Tesaglitazar has one completed clinical trial registered under NCT00280865, titled 'GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes.' This Phase 2 study enrolled 500 participants across the United States, Canada, France, and Mexico.
Yes, Tesaglitazar is also known as AZ 242. The clinical trial NCT00280865 refers to the drug as AZ 242 (Tesaglitazar), confirming that these names refer to the same investigational compound.